Identification
NameINGN 201
Accession NumberDB05322
TypeBiotech
GroupsInvestigational
Description

INGN 201(Advexin) is a replication-impaired adenoviral vector that carries the p53 gene, has been evaluated in both preclinical and clinical trials. Advexin is a well-tolerated and efficacious treatment for numerous cancers, both as monotherapy and in combination with radiation and/or chemotherapy agents.

Protein structureNo structure small
Related Articles
Protein chemical formulaNot Available
Protein average weightNot Available
SequencesNot Available
SynonymsNot Available
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AdvexinNot Available
Brand mixturesNot Available
Categories
UNIINot Available
CAS numberNot Available
Pharmacology
Indication

Investigated for use/treatment in bladder cancer, brain cancer, breast cancer, esophageal cancer, head and neck cancer, lung cancer, oral cavity cancer, ovarian cancer, and prostate cancer.

Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action

Advexin® is a vaccine that contains very high concentrations of the p53 protein. Advexin® is administered into or near the site of cancer and has demonstrated the ability to make cancer cells more sensitive to the killing effects of chemotherapy. The p53 gene makes protein that is responsible for stopping uncontrolled growth of a cell. One of its roles is to stop growth of a cell and initiate repair of any detected mutations or damage within the DNA of the cell. In addition, the p53 gene will direct the cell to destroy itself if a mutation or damage is detected that is beyond repair.

Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with INGN 201.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with INGN 201.Experimental, Illicit
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with INGN 201.Experimental
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with INGN 201.Experimental, Illicit
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with INGN 201.Approved
AbciximabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Abciximab.Approved
ActeosideThe risk or severity of adverse effects can be increased when Acteoside is combined with INGN 201.Investigational
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with INGN 201.Approved
AdecatumumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with MT201.Investigational
Adefovir DipivoxilThe risk or severity of adverse effects can be increased when Adefovir Dipivoxil is combined with INGN 201.Approved, Investigational
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with INGN 201.Investigational
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with INGN 201.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with INGN 201.Experimental
AlefaceptThe risk or severity of adverse effects can be increased when Alefacept is combined with INGN 201.Approved, Withdrawn
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with INGN 201.Approved, Investigational
AlirocumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Alirocumab.Approved
AltretamineThe risk or severity of adverse effects can be increased when Altretamine is combined with INGN 201.Approved
AmatuximabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Amatuximab.Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with INGN 201.Approved
AmsacrineThe risk or severity of adverse effects can be increased when Amsacrine is combined with INGN 201.Approved
AnakinraThe risk or severity of adverse effects can be increased when Anakinra is combined with INGN 201.Approved
AndrostenedioneThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with INGN 201.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with INGN 201.Investigational
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Anti-thymocyte Globulin (Rabbit) is combined with INGN 201.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with INGN 201.Approved, Investigational
Asfotase AlfaThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Asfotase Alfa.Approved, Investigational
AtezolizumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Atezolizumab.Approved
AvelumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Avelumab.Approved
AzacitidineThe risk or severity of adverse effects can be increased when Azacitidine is combined with INGN 201.Approved, Investigational
AzathioprineThe risk or severity of adverse effects can be increased when Azathioprine is combined with INGN 201.Approved
BasiliximabThe risk or severity of adverse effects can be increased when Basiliximab is combined with INGN 201.Approved, Investigational
BavituximabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Bavituximab.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with INGN 201.Approved, Investigational
BectumomabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Bectumomab.Investigational
BelataceptThe risk or severity of adverse effects can be increased when Belatacept is combined with INGN 201.Approved
BelimumabThe risk or severity of adverse effects can be increased when Belimumab is combined with INGN 201.Approved
BenralizumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Medi 563.Investigational
BenznidazoleThe risk or severity of adverse effects can be increased when Benznidazole is combined with INGN 201.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with INGN 201.Approved, Vet Approved
BevacizumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Bevacizumab.Approved, Investigational
BimagrumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Bym338.Investigational
BleomycinThe risk or severity of adverse effects can be increased when Bleomycin is combined with INGN 201.Approved
BlinatumomabThe risk or severity of adverse effects can be increased when Blinatumomab is combined with INGN 201.Approved
BlosozumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Ly2541546.Investigational
BococizumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Pf 04950615.Investigational
Brentuximab vedotinThe risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with INGN 201.Approved
BriakinumabThe risk or severity of adverse effects can be increased when Briakinumab is combined with INGN 201.Investigational
BrodalumabThe risk or severity of adverse effects can be increased when Amg 827 is combined with INGN 201.Approved, Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with INGN 201.Approved
BusulfanThe risk or severity of adverse effects can be increased when Busulfan is combined with INGN 201.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with INGN 201.Approved
CanakinumabThe risk or severity of adverse effects can be increased when Canakinumab is combined with INGN 201.Approved, Investigational
CapecitabineThe risk or severity of adverse effects can be increased when Capecitabine is combined with INGN 201.Approved, Investigational
Capromab pendetideThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Capromab.Approved
CarboplatinThe risk or severity of adverse effects can be increased when Carboplatin is combined with INGN 201.Approved
CarmustineThe risk or severity of adverse effects can be increased when Carmustine is combined with INGN 201.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with INGN 201.Experimental
Certolizumab pegolThe risk or severity of adverse effects can be increased when Certolizumab pegol is combined with INGN 201.Approved
CetuximabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Cetuximab.Approved
ChlorambucilThe risk or severity of adverse effects can be increased when Chlorambucil is combined with INGN 201.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with INGN 201.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Cisplatin is combined with INGN 201.Approved
CladribineThe risk or severity of adverse effects can be increased when Cladribine is combined with INGN 201.Approved, Investigational
ClazakizumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Clazakizumab.Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with INGN 201.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with INGN 201.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with INGN 201.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with INGN 201.Approved, Investigational
CMC-544The therapeutic efficacy of INGN 201 can be decreased when used in combination with CMC-544.Investigational
ConcizumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Concizumab.Investigational
CorticotropinThe risk or severity of adverse effects can be increased when Corticotropin is combined with INGN 201.Approved, Vet Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with INGN 201.Approved
CR002The therapeutic efficacy of INGN 201 can be decreased when used in combination with CR002.Investigational
CrotedumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Regn1193.Investigational
CyclophosphamideThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with INGN 201.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with INGN 201.Approved, Investigational, Vet Approved
CytarabineThe risk or severity of adverse effects can be increased when Cytarabine is combined with INGN 201.Approved, Investigational
DacarbazineThe risk or severity of adverse effects can be increased when Dacarbazine is combined with INGN 201.Approved, Investigational
DacetuzumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Dacetuzumab.Investigational
DaclizumabThe risk or severity of adverse effects can be increased when Daclizumab is combined with INGN 201.Approved, Investigational
DactinomycinThe risk or severity of adverse effects can be increased when Dactinomycin is combined with INGN 201.Approved
DalotuzumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Dalotuzumab.Investigational
DaratumumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Daratumumab.Approved
DasatinibThe risk or severity of adverse effects can be increased when Dasatinib is combined with INGN 201.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Daunorubicin is combined with INGN 201.Approved
DenosumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Denosumab.Approved
DeoxyspergualinThe risk or severity of adverse effects can be increased when Deoxyspergualin is combined with INGN 201.Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with INGN 201.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with INGN 201.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with INGN 201.Approved, Investigational, Vet Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with INGN 201.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with INGN 201.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with INGN 201.Approved
Dimethyl fumarateThe risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with INGN 201.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with INGN 201.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with INGN 201.Approved, Investigational
DoxifluridineThe risk or severity of adverse effects can be increased when Doxifluridine is combined with INGN 201.Investigational
DoxorubicinThe risk or severity of adverse effects can be increased when Doxorubicin is combined with INGN 201.Approved, Investigational
DulaglutideThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Dulaglutide.Approved
DupilumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Dupilumab.Approved, Investigational
DurvalumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Medi4736.Approved
EculizumabThe risk or severity of adverse effects can be increased when Eculizumab is combined with INGN 201.Approved, Investigational
EfalizumabThe risk or severity of adverse effects can be increased when Efalizumab is combined with INGN 201.Approved, Investigational
ElotuzumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Elotuzumab.Approved
EmibetuzumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Ly2875358.Investigational
EpirubicinThe risk or severity of adverse effects can be increased when Epirubicin is combined with INGN 201.Approved
EpratuzumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Epratuzumab.Investigational
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with INGN 201.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with INGN 201.Approved
EstramustineThe risk or severity of adverse effects can be increased when Estramustine is combined with INGN 201.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with INGN 201.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with INGN 201.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with INGN 201.Approved, Investigational
EtaracizumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Medi 522.Investigational
EtoposideThe risk or severity of adverse effects can be increased when Etoposide is combined with INGN 201.Approved
EtrolizumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Etrolizumab.Investigational
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with INGN 201.Approved
EvolocumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Evolocumab.Approved
FarletuzumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Farletuzumab.Investigational
FiclatuzumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Ficlatuzumab.Investigational
FingolimodThe risk or severity of adverse effects can be increased when Fingolimod is combined with INGN 201.Approved, Investigational
FirategrastThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Sb 683699.Investigational
FloxuridineThe risk or severity of adverse effects can be increased when Floxuridine is combined with INGN 201.Approved
FludarabineThe risk or severity of adverse effects can be increased when Fludarabine is combined with INGN 201.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with INGN 201.Approved
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with INGN 201.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with INGN 201.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with INGN 201.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with INGN 201.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with INGN 201.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with INGN 201.Approved
FluorouracilThe risk or severity of adverse effects can be increased when Fluorouracil is combined with INGN 201.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with INGN 201.Approved, Withdrawn
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with INGN 201.Approved
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with INGN 201.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with INGN 201.Approved
FontolizumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Fontolizumab.Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with INGN 201.Approved, Investigational, Withdrawn
FresolimumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Fresolimumab.Investigational
FulranumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Jnj 42160443.Investigational
GaliximabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Galiximab.Investigational
Gallium nitrateThe risk or severity of adverse effects can be increased when Gallium nitrate is combined with INGN 201.Approved, Investigational
GemcitabineThe risk or severity of adverse effects can be increased when Gemcitabine is combined with INGN 201.Approved
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with INGN 201.Approved, Investigational, Withdrawn
GevokizumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Gevokizumab.Investigational
Glatiramer AcetateThe risk or severity of adverse effects can be increased when Glatiramer Acetate is combined with INGN 201.Approved, Investigational
GlimepirideThe risk or severity of adverse effects can be increased when Glimepiride is combined with INGN 201.Approved
GolimumabThe risk or severity of adverse effects can be increased when Golimumab is combined with INGN 201.Approved
GuselkumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Cnto 1959.Investigational
GusperimusThe risk or severity of adverse effects can be increased when Gusperimus is combined with INGN 201.Investigational
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with INGN 201.Investigational
Human C1-esterase inhibitorThe risk or severity of adverse effects can be increased when C1 Esterase Inhibitor (Human) is combined with INGN 201.Approved
Human Varicella-Zoster Immune GlobulinThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Human Varicella-Zoster Immune Globulin.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with INGN 201.Approved, Vet Approved
HydroxyureaThe risk or severity of adverse effects can be increased when Hydroxyurea is combined with INGN 201.Approved
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with INGN 201.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with INGN 201.Approved
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with INGN 201.Approved
IdarubicinThe risk or severity of adverse effects can be increased when Idarubicin is combined with INGN 201.Approved
IdarucizumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Idarucizumab.Approved
IdelalisibThe risk or severity of adverse effects can be increased when Idelalisib is combined with INGN 201.Approved
IfosfamideThe risk or severity of adverse effects can be increased when Ifosfamide is combined with INGN 201.Approved
IGN311The therapeutic efficacy of INGN 201 can be decreased when used in combination with IGN311.Investigational
ImatinibThe risk or severity of adverse effects can be increased when Imatinib is combined with INGN 201.Approved
IMC-1C11The therapeutic efficacy of INGN 201 can be decreased when used in combination with IMC-1C11.Investigational
ImiquimodThe risk or severity of adverse effects can be increased when Imiquimod is combined with INGN 201.Approved, Investigational
Immune Globulin HumanThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Immune Globulin Human.Approved, Investigational
InclacumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Ro4905417.Investigational
InfliximabThe risk or severity of adverse effects can be increased when Infliximab is combined with INGN 201.Approved
IntetumumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Intetumumab.Investigational
IpilimumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Ipilimumab.Approved
IrinotecanThe risk or severity of adverse effects can be increased when Irinotecan is combined with INGN 201.Approved, Investigational
IxekizumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Ixekizumab.Approved, Investigational
L-PhenylalanineThe risk or severity of adverse effects can be increased when L-Phenylalanine is combined with INGN 201.Approved, Nutraceutical
LabetuzumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Labetuzumab.Investigational
LampalizumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Fcfd4514 S.Investigational
LandogrozumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Ly2495655.Investigational
LebrikizumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Lebrikizumab.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with INGN 201.Approved, Investigational
LenalidomideThe risk or severity of adverse effects can be increased when Lenalidomide is combined with INGN 201.Approved
LigelizumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Qge031.Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with INGN 201.Investigational
LomustineThe risk or severity of adverse effects can be increased when Lomustine is combined with INGN 201.Approved
Lorvotuzumab mertansineThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Imgn901.Investigational
MatuzumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Matuzumab.Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with INGN 201.Investigational
MechlorethamineThe risk or severity of adverse effects can be increased when Mechlorethamine is combined with INGN 201.Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with INGN 201.Approved
MelphalanThe risk or severity of adverse effects can be increased when Melphalan is combined with INGN 201.Approved
MepolizumabThe risk or severity of adverse effects can be increased when Mepolizumab is combined with INGN 201.Approved, Investigational
MercaptopurineThe risk or severity of adverse effects can be increased when Mercaptopurine is combined with INGN 201.Approved
MethotrexateThe risk or severity of adverse effects can be increased when Methotrexate is combined with INGN 201.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with INGN 201.Approved, Vet Approved
Mirvetuximab SoravtansineThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Mirvetuximab Soravtansine.Investigational
MitomycinThe risk or severity of adverse effects can be increased when Mitomycin is combined with INGN 201.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Mitoxantrone is combined with INGN 201.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with INGN 201.Investigational
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with INGN 201.Approved, Vet Approved
MuromonabThe risk or severity of adverse effects can be increased when Muromonab is combined with INGN 201.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with INGN 201.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with INGN 201.Approved
MYO-029The therapeutic efficacy of INGN 201 can be decreased when used in combination with MYO-029.Investigational
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with INGN 201.Approved, Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Natalizumab is combined with INGN 201.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with INGN 201.Investigational
NecitumumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Necitumumab.Approved
NelarabineThe risk or severity of adverse effects can be increased when Nelarabine is combined with INGN 201.Approved, Investigational
NilotinibThe risk or severity of adverse effects can be increased when Nilotinib is combined with INGN 201.Approved, Investigational
NivolumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Nivolumab.Approved
ObiltoxaximabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Obiltoxaximab.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with INGN 201.Approved
OfatumumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Ofatumumab.Approved
OlaratumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Olaratumab.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl estrone is combined with INGN 201.Investigational
OlokizumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Cdp6038.Investigational
OmalizumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Omalizumab.Approved, Investigational
OnartuzumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Onartuzumab.Investigational
OregovomabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Oregovomab.Investigational
OtelixizumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with TRX4.Investigational
OxaliplatinThe risk or severity of adverse effects can be increased when Oxaliplatin is combined with INGN 201.Approved, Investigational
OzanezumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Gsk1223249.Investigational
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with INGN 201.Approved, Vet Approved
PalbociclibThe risk or severity of adverse effects can be increased when Palbociclib is combined with INGN 201.Approved
PalivizumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Palivizumab.Approved, Investigational
PanitumumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Panitumumab.Approved, Investigational
PanobinostatThe risk or severity of adverse effects can be increased when Panobinostat is combined with INGN 201.Approved, Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with INGN 201.Approved
PatritumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Patritumab.Investigational
PazopanibThe risk or severity of adverse effects can be increased when Pazopanib is combined with INGN 201.Approved
PegaspargaseThe risk or severity of adverse effects can be increased when Pegaspargase is combined with INGN 201.Approved, Investigational
PembrolizumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Pembrolizumab.Approved
PemetrexedThe risk or severity of adverse effects can be increased when Pemetrexed is combined with INGN 201.Approved, Investigational
PentostatinThe risk or severity of adverse effects can be increased when Pentostatin is combined with INGN 201.Approved, Investigational
PertuzumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Pertuzumab.Approved
PexelizumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Pexelizumab.Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with INGN 201.Approved, Investigational
PirarubicinThe risk or severity of adverse effects can be increased when Pirarubicin is combined with INGN 201.Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with INGN 201.Investigational
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with INGN 201.Approved
PralatrexateThe risk or severity of adverse effects can be increased when Pralatrexate is combined with INGN 201.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with INGN 201.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with INGN 201.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with INGN 201.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with INGN 201.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with INGN 201.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with INGN 201.Experimental
PRO-542The therapeutic efficacy of INGN 201 can be decreased when used in combination with PRO-542.Investigational
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with INGN 201.Approved
RacotumomabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Racotumomab.Investigational
RamucirumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Ramucirumab.Approved, Investigational
RanibizumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Ranibizumab.Approved
RaxibacumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Raxibacumab.Approved
RI 624The therapeutic efficacy of INGN 201 can be decreased when used in combination with RI 624.Investigational
RIGScan CR49The therapeutic efficacy of INGN 201 can be decreased when used in combination with RIGScan CR49.Investigational
RilonaceptThe risk or severity of adverse effects can be increased when Rilonacept is combined with INGN 201.Approved
RilotumumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Rilotumumab.Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with INGN 201.Approved
RituximabThe risk or severity of adverse effects can be increased when Rituximab is combined with INGN 201.Approved
RobatumumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Sch 717454.Investigational
RontalizumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Rontalizumab.Investigational
RuxolitinibThe risk or severity of adverse effects can be increased when Ruxolitinib is combined with INGN 201.Approved
SecukinumabThe risk or severity of adverse effects can be increased when Secukinumab is combined with INGN 201.Approved
SeocalcitolThe risk or severity of adverse effects can be increased when Seocalcitol is combined with INGN 201.Experimental
SeribantumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Mm 121.Investigational
SiltuximabThe risk or severity of adverse effects can be increased when Siltuximab is combined with INGN 201.Approved
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with INGN 201.Approved, Investigational
SorafenibThe risk or severity of adverse effects can be increased when Sorafenib is combined with INGN 201.Approved, Investigational
SteproninThe risk or severity of adverse effects can be increased when Stepronin is combined with INGN 201.Approved
StreptozocinThe risk or severity of adverse effects can be increased when Streptozocin is combined with INGN 201.Approved
SunitinibThe risk or severity of adverse effects can be increased when Sunitinib is combined with INGN 201.Approved, Investigational
SYM001The therapeutic efficacy of INGN 201 can be decreased when used in combination with SYM001.Investigational
TabalumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Ly2127399.Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with INGN 201.Approved, Investigational
TanezumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Rn624.Investigational
Technetium Tc-99m arcitumomabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Arcitumomab.Approved, Investigational
TemozolomideThe risk or severity of adverse effects can be increased when Temozolomide is combined with INGN 201.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with INGN 201.Approved
TeniposideThe risk or severity of adverse effects can be increased when Teniposide is combined with INGN 201.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with INGN 201.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with INGN 201.Approved, Investigational, Withdrawn
ThiotepaThe risk or severity of adverse effects can be increased when Thiotepa is combined with INGN 201.Approved
TioguanineThe risk or severity of adverse effects can be increased when Tioguanine is combined with INGN 201.Approved
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with INGN 201.Approved
TNX-901The therapeutic efficacy of INGN 201 can be decreased when used in combination with TNX-901.Investigational
TocilizumabThe risk or severity of adverse effects can be increased when Tocilizumab is combined with INGN 201.Approved
TofacitinibThe risk or severity of adverse effects can be increased when Tofacitinib is combined with INGN 201.Approved, Investigational
TopotecanThe risk or severity of adverse effects can be increased when Topotecan is combined with INGN 201.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Tositumomab is combined with INGN 201.Approved
TrabectedinThe risk or severity of adverse effects can be increased when Trabectedin is combined with INGN 201.Approved, Investigational
TrastuzumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Trastuzumab.Approved, Investigational
Trastuzumab emtansineThe risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with INGN 201.Approved
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with INGN 201.Approved, Investigational, Nutraceutical
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with INGN 201.Approved, Vet Approved
TrofosfamideThe risk or severity of adverse effects can be increased when Trofosfamide is combined with INGN 201.Investigational
UstekinumabThe risk or severity of adverse effects can be increased when Ustekinumab is combined with INGN 201.Approved, Investigational
VedolizumabThe risk or severity of adverse effects can be increased when Vedolizumab is combined with INGN 201.Approved
VilanterolThe risk or severity of adverse effects can be increased when Vilanterol is combined with INGN 201.Approved
VinblastineThe risk or severity of adverse effects can be increased when Vinblastine is combined with INGN 201.Approved
VincristineThe risk or severity of adverse effects can be increased when Vincristine is combined with INGN 201.Approved, Investigational
VindesineThe risk or severity of adverse effects can be increased when Vindesine is combined with INGN 201.Approved
VinorelbineThe risk or severity of adverse effects can be increased when Vinorelbine is combined with INGN 201.Approved, Investigational
VoclosporinThe risk or severity of adverse effects can be increased when Lx211 is combined with INGN 201.Investigational
XTL-001The therapeutic efficacy of INGN 201 can be decreased when used in combination with XTL-001.Investigational
ZalutumumabThe therapeutic efficacy of INGN 201 can be decreased when used in combination with Zalutumumab.Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Authors unspecified: INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201. Drugs R D. 2007;8(3):176-87. [PubMed:17472413 ]
  2. Gabrilovich DI: INGN 201 (Advexin): adenoviral p53 gene therapy for cancer. Expert Opin Biol Ther. 2006 Aug;6(8):823-32. [PubMed:16856803 ]
External LinksNot Available
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentRecurrent Bladder Cancer / Stage I Bladder Cancer / Stage II Bladder Cancer / Stage III Bladder Cancer / Stage IV Bladder Cancer / Transitional Cell Carcinoma of the Bladder1
1, 2CompletedPreventionLip and Oral Cavity Cancer / Oropharyngeal Cancers / Stage 0 Lip and Oral Cavity Cancer / Stage 0 Oropharyngeal Cancer / Tongue Cancer1
2TerminatedTreatmentHead and Neck Carcinoma1
Not AvailableWithdrawnDiagnosticCancer, Breast1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available
Drug created on November 18, 2007 11:23 / Updated on August 17, 2016 12:24